Concise guide to pharmacology simplifies drug discovery research

October 26, 2017

The Concise Guide to PHARMACOLOGY 2017/18 is now available in the British Journal of Pharmacology. Published by Wiley on behalf of the British Pharmacological Society, the 440 page guide includes overviews of key properties for close to 1,700 human drug targets, identifies 3,500 ligands including more than 2,400 synthetic organic molecules and over 50 antibodies. Over 4,000 interactions between ligands and targets are quantified, allowing researchers to assess the potency of these interactions.

This open access knowledgebase of major drug targets is completely linked and divided into eight major areas of research focus:

"As a pharmacologist, being able to access freely information on current human drug targets is vital to discovering new therapeutics," said Steve Alexander, Associate Professor of Molecular Pharmacology, Faculty of Medicine & Health Sciences at the University of Nottingham and Lead Editor of the Concise Guide.

The Concise Guide provides an authoritative voice on nomenclature of these pharmacological targets through close links with NC-IUPHAR. It offers summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.

"The Concise Guide to PHARMACOLOGY is the drug discovery researchers' bible," said Amrita Ahluwalia, Co-Director, The William Harvey Research Institute, Professor of Vascular Pharmacology at Barts & The London School of Medicine & Dentistry, and Editor-in-Chief of the British Journal of Pharmacology. "We are pleased to once again make the Concise Guide freely available to our colleagues around the globe at http://www.guidetopharmacology.org/concise."

This edition of the Concise Guide was compiled with the help of over 150 collaborators representing industry and academia from 22 countries across four continents. The British Pharmacological Society would like to thank the Universities of Cambridge, Edinburgh, Nottingham in the UK, and Monash, Australia for their contributions to updating the Concise Guide to PHARMACOLOGY.
-end-
Additional Information

Full citation: (2017), Issue Information. British Journal of Pharmacology, 174: i-iv. doi:10.1111/bph.13987.

URL: http://bpspubs.onlinelibrary.wiley.com/hub/issue/10.1111/bph.v174.S1/

About the Journal

The British Journal of Pharmacology is a broad-based journal giving leading international coverage of all aspects of pharmacology research. Its scope includes all aspects of pharmacology from hypothesis generation and target validation through to model development, safety pharmacology and to early translational research. BJP's 2015 Impact Factor is 5.259, and as such it is a leading general research pharmacology journal (Thomson Reuters Science Citation Index).

About The British Pharmacological Society

The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. Founded in 1931, it is now a global community at the heart of pharmacology, with over 3,500 members from more than 60 countries worldwide. The Society leads the way in the research and application of pharmacology around the world through its scientific meetings, educational resources and peer-reviewed journals: the British Journal of Clinical Pharmacology, Pharmacology Research & Perspectives, and the British Journal of Pharmacology, which includes the Concise Guide to PHARMACOLOGY, featuring open access overviews of the key properties of over 1,700 human therapeutic targets and their drugs, and links to http://www.guidetopharmacology.org.

About Wiley

Wiley, a global research and learning company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

Wiley

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.